Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
| ▸ | CTSS | P25774 | 2/20 | 0.58 |
| ▸ | CTSK | P43235 | 1/20 | 0.58 |
| ▸ | TACR1 | P25103 | 9/20 | 0.54 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18625077 | 0.90 | TACR1 (0.53) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL16617939 | 0.89 | CTSL (0.65) | CTSLCTSBCTSSTACR1 | |
| SCHEMBL16617424 | 0.89 | TACR1 (0.59) | CTSLCTSBCTSSTACR1LNPEP | |
| SCHEMBL16618099 | 0.85 | TACR1 (0.59) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL16617786 | 0.84 | ITGB2 (0.64) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL10805861 | 0.84 | ITGB2 (0.64) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL4364556 | 0.80 | CTSL (0.63) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL8893500 | 0.80 | LTA4H (0.55) | CTSLTACR1 | |
| SCHEMBL8893493 | 0.80 | LTA4H (0.55) | CTSLTACR1 | |
| SCHEMBL4367288 | 0.79 | CTSL (0.58) | CTSLCTSBCTSSCTSKHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593144-B2 | FPR1 antagonist derivatives and use thereof | CHANG GUNG UNIVERSITY (TW) | 2017-03-14 | — | — | US | disclosed |
| US-20150307548-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | CHANG GUNG UNIVERSITY (TW) | 2015-10-29 | — | — | US | disclosed |
| US-20150099691-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | CHANG GUNG UNIVERSITY (TW) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307548-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | FPR1, FPR3, FPR2 | CTSL 957/4885CTSB 1415/4885CTSS 1757/4885 |
| US-20150099691-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | FPR1, FPR3, FPR2 | CTSL 957/4885CTSB 1415/4885CTSS 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.